150 related articles for article (PubMed ID: 38404578)
21. Association of PD-1/PD-L1 expression and Epstein--Barr virus infection in patients with invasive breast cancer.
Zhang WT; Zhu GL; Xu WQ; Zhang W; Wang HZ; Wang YB; Li YX
Diagn Pathol; 2022 Jul; 17(1):61. PubMed ID: 35842661
[TBL] [Abstract][Full Text] [Related]
22. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
Seo AN; Kang BW; Kwon OK; Park KB; Lee SS; Chung HY; Yu W; Bae HI; Jeon SW; Kang H; Kim JG
Br J Cancer; 2017 Dec; 117(12):1753-1760. PubMed ID: 29073638
[TBL] [Abstract][Full Text] [Related]
23. Case Report: Durable Complete Response After Combined Immunotherapy Following Resection of Primary Tumor in a Gallbladder Cancer Patient With Distant Metastatic Lymph Nodes of Favorable Immune-Microenvironment.
Yi B; Zhao Z; Dong H; Yuan L; Wu Y; Xu Y; Jiang X; Sun C; Wu D; Xiao Y
Front Immunol; 2022; 13():820566. PubMed ID: 35242133
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
[TBL] [Abstract][Full Text] [Related]
25. Perspectives for immunotherapy of EBV-associated GLELC: A relatively "hot" tumor microenvironment.
Lei Y; Cao P; Zheng X; Wei J; Cheng M; Liu M
Cancer Med; 2023 Oct; 12(19):19838-19849. PubMed ID: 37732493
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
Kawazoe A; Shitara K; Kuboki Y; Bando H; Kojima T; Yoshino T; Ohtsu A; Ochiai A; Togashi Y; Nishikawa H; Doi T; Kuwata T
Gastric Cancer; 2019 Jan; 22(1):69-76. PubMed ID: 29859006
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis of the relationship between Epstein-Barr virus infection and clinicopathological features of patients with gastric carcinoma.
Li S; Du H; Wang Z; Zhou L; Zhao X; Zeng Y
Sci China Life Sci; 2010 Apr; 53(4):524-30. PubMed ID: 20596921
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer.
Park JH; Kim EK; Kim YH; Kim JH; Bae YS; Lee YC; Cheong JH; Noh SH; Kim H
Gastric Cancer; 2016 Oct; 19(4):1041-1051. PubMed ID: 26573601
[TBL] [Abstract][Full Text] [Related]
30. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.
Wei XL; Liu QW; Liu FR; Yuan SS; Li XF; Li JN; Yang AL; Ling YH
Oncoimmunology; 2021; 10(1):1938381. PubMed ID: 34235004
[TBL] [Abstract][Full Text] [Related]
31. Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis?
Moore A; Hikri E; Goshen-Lago T; Barkan T; Morgenstern S; Brook E; Maderer A; Roth W; Gordon N; Kashtan H; Brenner B; Moehler M; Aharon IB
BMC Cancer; 2020 Jan; 20(1):34. PubMed ID: 31937281
[TBL] [Abstract][Full Text] [Related]
32. Immune Landscape of Epstein-Barr Virus-Associated Gastric Cancer: Analysis From a Western Academic Institution.
Yee EJ; Gilbert D; Kaplan J; van Dyk L; Kim SS; Berg L; Clambey E; Wani S; McCarter MD; Stewart CL
J Surg Res; 2024 Apr; 296():742-750. PubMed ID: 38368775
[TBL] [Abstract][Full Text] [Related]
33. CT findings and clinical features of Epstein-Barr virus-associated lymphoepithelioma-like gastric carcinoma.
Liang P; Ren XC; Gao JB; Chen KS
Medicine (Baltimore); 2019 Apr; 98(14):e14839. PubMed ID: 30946311
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of preoperative immunotherapy alone followed by surgery in the treatment of advanced gastric cancer with MSI-H/dMMR or EBV-positive.
Lei X; Wang Y; Shan F; Li S; Jia Y; Miao R; Xue K; Li Z; Ji J; Li Z
J Chin Med Assoc; 2023 Aug; 86(8):717-724. PubMed ID: 37273199
[TBL] [Abstract][Full Text] [Related]
36. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
Masetti M; Lindinger M; Lorenzen S
Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
[TBL] [Abstract][Full Text] [Related]
37. Risk for lymph node metastasis in Epstein-Barr virus-associated gastric carcinoma with submucosal invasion.
Tsuji Y; Ushiku T; Shinozaki T; Yamashita H; Seto Y; Fukayama M; Fujishiro M; Oda I; Katai H; Taniguchi H; Hasatani K; Kaizaki Y; Oga A; Nishikawa J; Akasaka R; Endo M; Sugai T; Matsumoto T; Koike K
Dig Endosc; 2021 May; 33(4):592-597. PubMed ID: 32852875
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.
Nakano H; Saito M; Nakajima S; Saito K; Nakayama Y; Kase K; Yamada L; Kanke Y; Hanayama H; Onozawa H; Okayama H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Goto A; Kono K
Sci Rep; 2021 Jan; 11(1):1982. PubMed ID: 33479394
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A.
Truong CD; Feng W; Li W; Khoury T; Li Q; Alrawi S; Yu Y; Xie K; Yao J; Tan D
J Exp Clin Cancer Res; 2009 Feb; 28(1):14. PubMed ID: 19192297
[TBL] [Abstract][Full Text] [Related]
40. PARP1: A potential biomarker for gastric cancer.
Afzal H; Yousaf S; Rahman F; Ahmed MW; Akram Z; Akhtar Kayani M; Mahjabeen I
Pathol Res Pract; 2019 Aug; 215(8):152472. PubMed ID: 31174925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
